Mode
Text Size
Log in / Sign up

Poliomyelitis

Part of Picornaviridae Infections

12 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Poliomyelitis

53 trials tracked for Poliomyelitis: 40 in phase 3 or 4 and 16 with published results. The most-cited published study has 31 citations.

53Trials tracked
40Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 14 Phase 3 26 Phase 2 10 Phase 1 3
  1. Phase 3 A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV Completed · 31 cited
  2. Phase 4 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed · 28 cited
  3. Phase 4 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed · 26 cited
  4. Phase 4 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed · 19 cited
  5. Phase 3 Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. Completed · 19 cited
  6. Phase 3 Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children Completed · 16 cited
Show 44 more trials
  1. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
  2. Phase 4 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed · 12 cited
  3. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine Completed · 12 cited
  4. Phase 3 Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers Completed · 12 cited
  5. Phase 3 Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers Completed · 12 cited
  6. Phase 4 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed · 11 cited
  7. Phase 4 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed · 10 cited
  8. Phase 3 Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants Completed · 9 cited
  9. Phase 4 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed · 5 cited
  10. Phase 3 Confirmatory Study of BK1310 in Healthy Infants Completed · 1 cited
  11. Phase 4 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed
  12. Phase 4 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed
  13. Phase 4 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed
  14. Phase 4 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed
  15. Phase 4 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed
  16. Phase 4 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed
  17. Phase 4 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed
  18. Phase 3 Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine Completed
  19. Phase 3 Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) Completed
  20. Phase 3 Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine Completed
  21. Phase 3 Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Completed
  22. Phase 3 Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Completed
  23. Phase 3 Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine Completed
  24. Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants Completed
  25. Phase 3 A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants Completed
  26. Phase 3 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth Completed
  27. Phase 3 Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Completed
  28. Phase 3 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) Completed
  29. Phase 3 Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines Completed
  30. Phase 3 Immunogenicity and Safety of Adacel Polio Vaccine Completed
  31. Phase 3 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Completed
  32. Phase 3 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ Completed
  33. Phase 3 Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Completed
  34. Phase 3 Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants Completed
  35. Phase 2 Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age Completed
  36. Phase 2 A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine Completed
  37. Phase 2 A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Completed
  38. Phase 2 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  39. Phase 2 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  40. Phase 2 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants Completed
  41. Phase 2 Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Completed
  42. Phase 2 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose Completed
  43. Phase 2 Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Completed
  44. Phase 2 Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Completed

Showing the 50 most-cited and recently-updated of 53 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Poliomyelitis

What data does the report describe regarding Poliovirus in high-risk countries?

Reports describe poliovirus surveillance data from 40 high-risk countries, noting that Afghanistan, Pakistan, and Nigeria remain the only places with ongoing wild poliovirus transmission.

Full answer →
Which 39 countries reported vaccine-derived poliovirus cases during the 2023 to 2024 period?

According to a 2024 surveillance report, 39 countries reported cases of vaccine-derived poliovirus between January 2023 and June 2024 [5].

Full answer →
How did the number of wild poliovirus cases change in Pakistan recently?

Wild poliovirus cases in Pakistan increased significantly between 2018 and 2019, and a later report documents changes in case numbers from 2022 through 2024.

Full answer →